Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- XBI.MX
- Price
- 2200.00
- Stock movement up
- +- (%)
- Company name
- SPDR Series Trust - SPDR S&P Biotech ETF
- Exchange
- (MX ,
- Currency
- MXN )
- Market cap
- -
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -11.21%
- 3 year return
- -5.61%
- 5 year return
- -8.74%
- 10 year return
- 34.74%
Last updated: 2025-09-03
DIVIDENDS
XBI.MX does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1597.85 |
| Daily high | 1597.85 |
| Daily low | 1597.85 |
| Daily Volume | 0K |
| All-time high | 3472.01 |
| 1y analyst estimate | - |
| Beta | - |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | 23 Jun 2025 |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| XBI.MX | S&P500 | |
| Current price drop from All-time high | -36.64% | -2.71% |
| Highest price drop | -96.80% | -19.00% |
| Date of highest drop | 11 Feb 2016 | 8 Apr 2025 |
| Avg drop from high | -44.29% | -2.73% |
| Avg time to new high | 28 days | 6 days |
| Max time to new high | 1137 days | 89 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Mid-cap
Description
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index (S&P TMI).
Employees
Investor relations
-
SEC filings
CEO
Country
Mexico
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Smart Beta ETF report for XBI
November 19, 2025
Halda is testing a prostate cancer drug. J&J says that with the acquisition it will gain a platform for treating “diseases beyond oncology.”
November 17, 2025
XBI hits a fresh 52-week high after a sharp rebound in biotech momentum fueled by favorable regulation, valuations and improving funding trends.
November 17, 2025
Merck has agreed to pay a hefty premium for a biotech making a new flu prevention drug, as it braces for the expiration of the patents protecting its top-selling cancer treatment Keytruda. It is the ...
November 14, 2025
Dr. Richard Pazdur is “likely the best possible person for the role,” says one analyst. A calmer course for the FDA could add fuel to the recent run-up in biotech stocks.
November 12, 2025
The long-anticipated news that Novartis will buy the rare-disease company Avidity Biosciences amounts to yet another bullish sign for the biotech sector, which has been ripping this fall after yea...
October 27, 2025
The strong earnings report from Medpace Holdings which runs clinical trials to test biotech companies’ new drugs, offers more evidence that the biotech sector is on the rebound. Medpace said late W...
October 23, 2025
We recently published 10 Trending Stocks This Week. SPDR S&P Biotech ETF (NYSEARCA:XBI) is one of the trending stocks this week. Joseph Terranova, Senior Managing Director, Virtus Investment Partners,...
October 21, 2025
Barron’s called Holz to ask about what’s happened to the biotech sector since our healthcare roundtable.
October 17, 2025
The Trump administration has promised to delay sector-specific tariffs for both firms, and more drugmakers could join the club.
October 13, 2025
Next page